Innoviva vs Pharming
INVA and PHAR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INVA and PHAR compare
Pharming grew revenue faster over the last twelve months (26.6% versus 12.8% for Innoviva).
Innoviva scores higher on the StockData Score (14 against 8 for Pharming), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INVA | PHAR |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $19.03 | $12.60 |
| Change, 1 year | −14.6% | −26.5% |
| Change, 5 years | 11.6% | 46.2% |
| Beta (5Y) | 0.23 | 0.55 |
| Employees | 159 | 50K |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.7× | – |
| P/S | 3.1× | – |
| P/B | 1.2× | – |
| EV/EBITDA | 6.2× | – |
| P/FCF | 7.5× | – |
| PEG | 0.83 | – |
| FCF yield | 13.3% | – |
| Fair value | $31.77 | – |
| Margin of safety | 40.1% | – |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 26.6% (better) |
| Revenue growth, 5Y average | 4.1% | 12.1% (better) |
| EPS growth, 5Y average | 10.3% (better) | −40.8% |
| Profitability | ||
| Gross margin | 74.5% | 87.9% (better) |
| Operating margin | 38.8% (better) | 6.9% |
| Net margin | – | 0.76% |
| FCF margin | 41.6% (better) | 14.3% |
| Return on invested capital | 18.0% | – |
| Financial health | ||
| Debt / equity | 0.23 | – |
| Net debt / EBITDA | −1.90 | – |
| Interest coverage | 8.6× | 132× (better) |
| Current ratio | 15.44 (better) | 2.59 |
| Altman Z-score | 3.55 | – |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Buyback yield | 5.7% | – |
| Shareholder yield | 5.7% | – |
| Ownership | ||
| Held by institutions | 104% | 0.32% |
| Held by insiders | 5.4% | 0.00% |
| Short interest, % of float | 11.0% | – |
Go deeper
- INVA stock overview
- INVA income statement
- INVA valuation and score
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.